FibroBiologics, Inc. entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC to issue and sell up to $6,150,000 of common stock for working capital and general corporate purposes.
Key takeaways
Entered ATM Sales Agreement with H.C. Wainwright on May 1, 2026 for up to $6.15M common stock.
Sales agent commission is 3.0% of gross proceeds.
Reimburses agent $100,000 upfront legal fees plus due diligence costs.
Proceeds for working capital and general corporate purposes.
No obligation to sell shares; offering terminates at $6.15M or agreement end.
Pursuant to effective S-3 registration (No. 333-284663).